Cancer Therapy News and Research

RSS

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

CTCA offers hope to Hispanics with advanced stage cancer

For the nation's fastest growing population, cancer ranked as the number one leading cause of death among Hispanics, based on a 2012 American Cancer Society report.

6 Jun 2013

Accuray announces treatment of first patient with new TomoHDA System

Accuray Incorporated, announced today the first patient has been treated with its new TomoHDA System at Centre Oscar Lambret in Lille, France.

5 Jun 2013

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society's highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO's 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.

5 Jun 2013

Report: 83% of cancer doctors face oncology drug shortages

Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510).

4 Jun 2013

Study brings researchers one step closer to personalized colorectal cancer treatment

MET protein levels correlate strongly with epithelial-mesenchymal transition phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology Meeting on Sunday, June 2.

From NanoString Technologies 1 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

Palm Beach Cancer Institute joins FCS family

Florida Cancer Specialists & Research Institute, the leading community-based oncology practice in the state, announced today that Palm Beach Cancer Institute will be joining the practice, effective June 1, 2013.

1 Jun 2013

Nanoparticle-based immunotherapy for cancer

The German Research Foundation has established a new Collaborative Research Center on "Nanodimensional polymer therapeutics for tumor therapy" (CRC 1066) at Johannes Gutenberg University Mainz and the Max Planck Institute for Polymer Research (MPI-P).

1 Jun 2013

Study: Young women with breast cancer often choose mastectomy over surgical procedure

A new study of young women with breast cancer has found that most chose to have a mastectomy rather than a surgical procedure that would conserve the breast, researchers will report at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31-June 4, in Chicago.

31 May 2013

Be ready for the next generation of cancer treatments

We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.

31 May 2013

Porter Cancer Care Center to use new image-guided radiotherapy system for cancer treatment

Starting June 2013, the Porter Cancer Care Center at Porter Adventist Hospital becomes one of the few facilities in the country to offer highly advanced radiation therapy and radiosurgery cancer treatment options using the new Varian TrueBeam image-guided radiotherapy system.

30 May 2013

Cancer Therapy News and Research

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

CTCA offers hope to Hispanics with advanced stage cancer

Accuray announces treatment of first patient with new TomoHDA System

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

Report: 83% of cancer doctors face oncology drug shortages

Study brings researchers one step closer to personalized colorectal cancer treatment

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Early detection methods can help cure cervical cancer

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Study shows utility of cfDNA blood tests for breast cancer patients

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

Palm Beach Cancer Institute joins FCS family

Nanoparticle-based immunotherapy for cancer

Study: Young women with breast cancer often choose mastectomy over surgical procedure

Be ready for the next generation of cancer treatments

Porter Cancer Care Center to use new image-guided radiotherapy system for cancer treatment

St James's Institute of Oncology orders two Versa HD systems to improve patient care

Study: Therapies targeting regulatory T cells could be a promising approach in cancer treatment

Study suggests possible way to halt cancer development in premalignant cells

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News